As part of its OncView video series, CancerNetwork spoke with Vijayakrishna (VK) Gadi, MD, PhD, University of Illinois College of Medicine, about the current role of genomic testing in HR-positive breast cancer and guidance on the use of genomic assays to individualize therapy in the extended adjuvant setting.

 

In the video series, Gadi discussed the following:

·      Adjuvant Vs Extended Adjuvant Therapy in HR+ Breast Cancer

·      Predictive and Prognostic Factors in HR+ Breast Cancer

·      Role of Genomic Testing in HR+ Breast Cancer

·      NCCN Guideline Updates for the Use of Genomic Assays in HR+ Breast Cancer

·      Identifying Patients for Extended Adjuvant Therapy With the Breast Cancer Index in HR+ Breast Cancer

·      Improving the Management of HR+ Breast Cancer: Next Steps

 

To watch more videos in CancerNetwork’s OncView series, visit cancernetwork.com.